Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Causative Role for Amylin in Diabetic Peripheral Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03481283
Recruitment Status : Recruiting
First Posted : March 29, 2018
Last Update Posted : April 26, 2021
Sponsor:
Information provided by (Responsible Party):
John Slevin, University of Kentucky

Brief Summary:

Three pieces of information lead to the basis for this study:

  1. Individuals with Type-2 diabetes commonly develop peripheral neuropathy.
  2. Increased production of the hormone amylin occurs in individuals who have Type-2 diabetes.
  3. Aggregations of amylin was found in the peripheral vasculature of rats that overexpressed human amylin.

The purpose of this study is to determine whether a correlation exists between the amount of amylin present in the upper extremities of human subjects with Type-2 diabetes and the extent to which symptoms of peripheral neuropathy are expressed in those subjects. The investigators will be testing this by initially collecting blood and skin biopsy samples from subjects, followed by measuring patient sensation and pain responses to heat, cold, and pressure in the upper extremities.


Condition or disease
Type2 Diabetes Peripheral Neuropathy

Detailed Description:

Impaired blood flow through microvessels (arterioles and capillaries) leads to irreversible damage to cells within the affected watershed. In addition to hypertension and age, Type-2 diabetes (DMII) independently contributes to microvascular disease. Distinct from other diabetic complications, the impact of diabetes on neurovascular function has not clearly been shown to correlate with measures of hyperglycemia or peripheral glucose regulation. The pathophysiology underlying the association between type-2 diabetes, vascular injury and neural damage, including CNS parenchymal loss and PNS neuropathy, remains uncertain.

Normally amylin, a byproduct of the synthesis of insulin by pancreatic β-cells, crosses the blood brain barrier and binds to neurons in feeding centers where it is believed to induce anorexic effects. Amylin aggregates are found in microvessels of pancreas, brain, hearts and kidneys of individuals with DMII or obesity. The investigators have demonstrated amylin aggregates in microvessels of peripheral nerves in rats overexpressing human amylin (unpublished). It is unknown whether amylin deposits are a consequence or a trigger of vascular injury, but they are clearly associated and may present a potential target for reducing diabetes-associated microvascular disease. Furthermore, their accumulation in peripheral nerve microvasculature and red blood cells (RBCs) offers possible foci for a peripheral biomarker of diabetes-induced CNS microvascular disease.

Hypothesis: Patients with DMII have significant amylin deposition in the peripheral vasa nervorum and on RBCs that correlates with severity of clinical peripheral polyneuropathy and reduction of peripheral nerve conduction velocities (NCVs); these amylin measures thereby become surrogates of microvascular disease and may serve as metrics of disease severity.

Aim: Obtain serum HbA1c, skin punch biopsy, RBCs, NCVs and clinical sensory examination from forty consenting adults previously diagnosed with DMII. Skin biopsy from volar forearm and red blood cell samples will be processed for amylin deposition.

This pilot study will provide preliminary data to fuel a larger, potentially multi-center, clinical trial investigating the utility of peripheral amylin or RBC amylin as a quantitative biomarker of microvascular disease that would include monitoring the effect of potential therapies. Measuring serum HbA1c will allow for possible correlation to chronic extracellular glucose concentration. Based on our preliminary data from a rat model of type-2 diabetes that expresses human amylin in the pancreas, the investigators anticipate an increased amylin deposition in the skin blood vessels with the progression of type-2 diabetes as measured by sensory examination and NCVs. Although not directly measured in this study, our preliminary data from the analysis of amylin deposition in cerebral blood vessels of patients with type-2 diabetes suggest that APOE 4 carriers, at risk for developing dementia, may have an increased propensity to accumulate amylin deposits in blood vessels. Thus, the ability to easily identify and target a potential driver of microvascular disease may help prevent the devastating effects of the vascular complications of DMII, including cardiovascular disease, retinopathy, nephropathy and dementia.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Causative Role for Amylin in Diabetic Peripheral Neuropathy
Actual Study Start Date : February 5, 2018
Estimated Primary Completion Date : February 28, 2022
Estimated Study Completion Date : February 28, 2022

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Red blood cell amylin level vs severity of peripheral neuropathy [ Time Frame: Single time point. Blood sample will be obtained from patient participant immediately after nerve conduction studies are performed. ]
    RBCs will be harvested from whole blood samples of participants and quantified RBC-bound amylin will be correlated with severity of nerve conduction velocities.

  2. Blood vessel wall amylin deposition vs severity of peripheral neuropathy [ Time Frame: Single time point. Skin biopsy will be obtained from patient participant immediately after nerve conduction studies are performed. ]
    A formalin-fixed 3 mm skin biopsy will be sectioned and stained with an anti-amylin antibody. Level of amylin deposition in blood vessel walls will be correlated with severity of peripheral neuropathy.


Secondary Outcome Measures :
  1. Pressure pain threshold vs RBC amylin and blood vessel wall amylin deposition [ Time Frame: Participants will undergo pressure test 1 week after providing blood and skin biopsy ]
    Participants' quantified pain threshold to applied pressure over the thenar eminence using a pressure algometer will be correlated to both RBC amylin and blood vessel wall amylin deposition.

  2. Cold pressor test vs RBC amylin and blood vessel wall amylin deposition [ Time Frame: Participants will undergo cold pressor test 1 week after providing blood and skin biopsy ]
    Participants' quantified pain threshold to a cold water bath (1 deg C) emmersion of their non-dominant forearm will be correlated to both RBC amylin and blood vessel wall amylin deposition.

  3. Heat thermode test vs RBC amylin and blood vessel wall amylin deposition [ Time Frame: Participants will undergo heat thermode test 1 week after providing blood and skin biopsy ]
    Participants' quantified pain threshold to a thermode placed on the dominant forearm will be correlated to both RBC amylin and blood vessel wall amylin deposition.


Biospecimen Retention:   Samples Without DNA
Obtaining blood samples and skin biopsy samples to measure amount of amylin present in those tissues.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Forty patients, age 18 years or older, with previously diagnosed DMII and referred to the Kentucky Neuroscience Institute Neuromuscular Laboratory for nerve conduction velocity studies (NCVs) will be asked to participate in the study. Because this is a pilot study, every effort will be made to select a broad distribution of male and female patients, regardless of ethnicity, who are mildly to severely symptomatic based on NCVs.
Criteria

Inclusion Criteria:

  • Subject has been diagnosed with Type-2 Diabetes.
  • Subject shows mild-to-severe peripheral neuropathy, as determined by Nerve Conduction Velocity (NCV) tests.

Exclusion Criteria:

  • Subject has not been diagnosed with Type-2 Diabetes.
  • Subject shows average, or above average performance on Nerve Conduction Velocity (NCV) tests.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03481283


Contacts
Layout table for location contacts
Contact: Rani Priyanka Vasireddy, MBBS, MHA 859-218-5076 rvasireddy@uky.edu
Contact: John T Slevin, M.D., M.B.A. 8593236702 jslevin@email.uky.edu

Locations
Layout table for location information
United States, Kentucky
UK Robert Straus Behavioral Science Laboratory Active, not recruiting
Lexington, Kentucky, United States, 40508
University of Kentucky - Kentucky Neuroscience Institute Recruiting
Lexington, Kentucky, United States, 40536
Contact: Rani Priyanka Vasireddy, MBBS, MHA    859-218-5076    rvasireddy@uky.edu   
Contact: John T Slevin, M.D., M.B.A.    8593236702    jslevin@email.uky.edu   
Principal Investigator: John T Slevin, MD, Ph.D.         
Sub-Investigator: Zabeen K Mahuwala, MD         
Sub-Investigator: Rani Priyanka Vasireddy, MBBS, MHA         
Sponsors and Collaborators
John Slevin
Investigators
Layout table for investigator information
Principal Investigator: John T Slevin, M.D., M.B.A. University of Kentucky Department of Neurology
  Study Documents (Full-Text)

Documents provided by John Slevin, University of Kentucky:
Study Protocol  [PDF] January 25, 2018

Layout table for additonal information
Responsible Party: John Slevin, Professor, Department of Neurology; Vice Chair for Research; Director, Movement Disorders Program, University of Kentucky
ClinicalTrials.gov Identifier: NCT03481283    
Other Study ID Numbers: 42732
First Posted: March 29, 2018    Key Record Dates
Last Update Posted: April 26, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by John Slevin, University of Kentucky:
Amylin
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases